Emily Minkow
Corporate Officer/Principal chez PREVAIL THERAPEUTICS INC.
Profil
Emily Minkow is currently the Director at Stylus Medicine, Inc. and a Venture Partner at RA Capital Management LP (Private Equity).
She was previously the Chief Business Officer at Prevail Therapeutics, Inc. and the Executive Director-Business Development at Celgene Corp.
Ms. Minkow received her undergraduate degree from Princeton University and her MBA from Harvard Business School.
Postes actifs de Emily Minkow
| Sociétés | Poste | Début |
|---|---|---|
| PREVAIL THERAPEUTICS INC. | Corporate Officer/Principal | 01/11/2018 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Private Equity Investor | 01/01/2022 |
Stylus Medicine, Inc.
 Stylus Medicine, Inc. Medical SpecialtiesHealth Technology Stylus Medicine, Inc. is a company focused on developing innovative solutions to combat diseases using cutting-edge genome engineering and chromatin regulation technologies. Stylus Medicine is based in Boston, MA. The company is backed by RA Ventures and Khosla Ventures. | Director/Board Member | - |
Anciens postes connus de Emily Minkow
| Sociétés | Poste | Fin |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 01/10/2017 |
Formation de Emily Minkow
| Princeton University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Prevail Therapeutics, Inc.
 Prevail Therapeutics, Inc. BiotechnologyHealth Technology Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson's disease and other neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY. | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Stylus Medicine, Inc.
Stylus Medicine, Inc. Medical SpecialtiesHealth Technology Stylus Medicine, Inc. is a company focused on developing innovative solutions to combat diseases using cutting-edge genome engineering and chromatin regulation technologies. Stylus Medicine is based in Boston, MA. The company is backed by RA Ventures and Khosla Ventures. | Health Technology |
